Brynn E Marks
Overview
Explore the profile of Brynn E Marks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gera S, Rearson A, Baker G, Douvas J, Alicea-Trelles N, Gallop R, et al.
J Clin Endocrinol Metab
. 2025 Jan;
PMID: 39813114
Objective: Glycemic outcomes in youth with type 1 diabetes (T1D) in the United States using the two most common automated insulin delivery (AID) systems, Insulet Omnipod 5 (OP5) and Tandem...
2.
Meighan S, Lipman T, VanGraafeiland B, Marks B
Sci Diabetes Self Manag Care
. 2025 Jan;
51(1):64-72.
PMID: 39783011
Purpose: The purpose of the study was to identify the most common reasons for and timing of continuous glucose monitoring (CGM) attrition in youth with type 1 diabetes (T1DM). Methods:...
3.
Marks B, Meighan S, Fivekiller E, Escobar E, Berget C
Horm Res Paediatr
. 2024 Oct;
:1-9.
PMID: 39406189
Introduction: Diabetic ketoacidosis (DKA) is the leading cause of mortality among youth with type 1 diabetes (T1D). Guidelines for DKA prevention exist; however, specific guidance about when to check ketones...
4.
Scully K, Marks B, Putman M
Diabetologia
. 2024 Jul;
67(10):2143-2153.
PMID: 38995399
People with cystic fibrosis (CF) are at risk for dysglycaemia caused by progressive beta cell dysfunction and destruction due to pancreatic exocrine disease and fibrosis. CF-related diabetes (CFRD) is a...
5.
Perkins A, Hinds P, Grundman J, Meighan S, Monaghan M, Streisand R, et al.
Diabet Med
. 2024 Jun;
41(11):e15382.
PMID: 38887129
Aims: There are marked inequities in clinical outcomes and rates of diabetes technology use among youth with type 1 diabetes (T1D). The quantitative data from our mixed methods cohort study...
6.
Meighan S, Douvas J, Rearson A, Squaresky R, Kelly A, Marks B
Diabetes Technol Ther
. 2024 May;
26(10):773-779.
PMID: 38805309
Youth starting Omnipod 5 (OP5) can onboard with a diabetes educator or self-start with support from online, industry-provided educational modules. We compared glycemic control and pump interaction by training type...
7.
Galderisi A, Marks B, DiMeglio L, de Beaufort C
Lancet Diabetes Endocrinol
. 2024 Apr;
12(5):297-299.
PMID: 38663944
No abstract available.
8.
Marks B, Grundman J, Meighan S, Monaghan M, Streisand R, Perkins A
Diabetes Technol Ther
. 2024 Mar;
26(3):167-175.
PMID: 38444316
We assessed changes in glycemic control and person-reported outcome measures (PROMs) with t:slim X2 insulin pump with Control-IQ technology use among historically minoritized youth who are least likely to access...
9.
Alkhatib E, Grundman J, Adamusiak A, Bellin M, Brooks J, Buckley K, et al.
Front Endocrinol (Lausanne)
. 2023 Nov;
14:1226231.
PMID: 37929017
Objective: Immediate type I, type III, and delayed type IV hypersensitivity reactions to insulin are rare, but potentially serious complications of exogenous insulin administration required for the treatment of type...
10.
Marks B, Meighan S, Zehra A, Douvas J, Rearson A, Suresh R, et al.
Diabetes Technol Ther
. 2023 Aug;
25(11):782-789.
PMID: 37646634
Pivotal trials of diabetes technologies have demonstrated glycemic improvements; however, these trials include patients of limited diversity and ranges of glycemic control. We assessed changes in glycemic control during the...